Index RUT
P/E -
EPS (ttm) -2.90
Insider Own 2.68%
Shs Outstand 69.93M
Perf Week -0.13%
Market Cap 1.36B
Forward P/E -
EPS next Y -3.28
Insider Trans -2.88%
Shs Float 68.05M
Perf Month -7.93%
Income -177.37M
PEG -
EPS next Q -1.00
Inst Own 89.91%
Short Float 7.87%
Perf Quarter -1.29%
Sales 133.62M
P/S 10.18
EPS this Y -91.04%
Inst Trans -2.00%
Short Ratio 10.14
Perf Half Y -5.19%
Book/sh 9.14
P/B 2.13
EPS next Y 17.43%
ROA -22.11%
Short Interest 5.36M
Perf Year 0.49%
Cash/sh 7.27
P/C 2.68
EPS next 5Y -
ROE -28.53%
52W Range 15.31 - 26.84
Perf YTD -8.36%
Dividend Est. -
P/FCF 51.61
EPS past 5Y -9.81%
ROI -27.55%
52W High -27.51%
Beta 0.67
Dividend TTM -
Quick Ratio 6.92
Sales past 5Y 70.11%
Gross Margin 90.70%
52W Low 27.07%
ATR (14) 0.80
Dividend Ex-Date -
Current Ratio 6.92
EPS Y/Y TTM -35.72%
Oper. Margin -128.78%
RSI (14) 49.07
Volatility 3.05% 4.06%
Employees 280
Debt/Eq 0.16
Sales Y/Y TTM 17.84%
Profit Margin -132.74%
Recom 1.55
Target Price 31.10
Option/Short Yes / Yes
LT Debt/Eq 0.14
EPS Q/Q -191.34%
Payout -
Rel Volume 0.28
Prev Close 19.65
Sales Surprise -15.20%
EPS Surprise -28.78%
Sales Q/Q -62.74%
Earnings Aug 05 AMC
Avg Volume 528.53K
Price 19.45
SMA20 -3.76%
SMA50 5.09%
SMA200 -5.42%
Trades
Volume 11,799
Change -0.99%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-16-24 Reiterated
BTIG Research
Buy
$56 → $38
Feb-28-24 Downgrade
Piper Sandler
Overweight → Neutral
$37 → $24
May-19-23 Initiated
BofA Securities
Buy
$42
Dec-06-22 Initiated
Cowen
Outperform
Oct-13-22 Upgrade
Raymond James
Outperform → Strong Buy
$58
Sep-21-22 Initiated
JP Morgan
Overweight
$37
Jul-06-22 Resumed
Canaccord Genuity
Buy
$50
Feb-11-22 Initiated
BMO Capital Markets
Outperform
$54
Jan-21-22 Initiated
SMBC Nikko
Outperform
$60
Dec-15-21 Initiated
H.C. Wainwright
Buy
$61
Oct-15-21 Resumed
BTIG Research
Buy
$56
Feb-24-21 Upgrade
Raymond James
Mkt Perform → Outperform
$58
Mar-04-20 Initiated
Barclays
Underweight
$28
Feb-25-20 Upgrade
Guggenheim
Neutral → Buy
$43
Jan-30-20 Initiated
RBC Capital Mkts
Outperform
$44
Nov-20-19 Resumed
Guggenheim
Neutral
Aug-07-19 Downgrade
Raymond James
Outperform → Mkt Perform
Aug-07-19 Downgrade
Guggenheim
Buy → Neutral
Jun-13-19 Initiated
Mizuho
Buy
Apr-12-19 Initiated
Guggenheim
Buy
Show Previous Ratings
Today 08:09AM
Oct-04-24 08:01AM
Sep-12-24 04:01PM
04:55AM
Sep-11-24 06:31AM
04:01PM
Loading…
Sep-10-24 04:01PM
Sep-09-24 07:31AM
Sep-06-24 08:01AM
Aug-05-24 09:55PM
05:15PM
04:12PM
(Associated Press Finance)
04:01PM
Jun-13-24 08:01AM
May-10-24 01:45PM
06:20AM
11:54PM
Loading…
May-09-24 11:54PM
05:18PM
(Associated Press Finance)
04:09PM
May-06-24 10:00AM
May-03-24 07:01PM
May-02-24 03:31AM
Apr-09-24 08:01AM
Mar-08-24 05:01PM
Mar-07-24 05:00PM
Feb-28-24 04:01PM
09:35AM
(Thomson Reuters StreetEvents)
08:38AM
Feb-27-24 05:20PM
04:39PM
04:26PM
(Associated Press Finance)
04:01PM
Loading…
04:01PM
Feb-20-24 04:31PM
Feb-19-24 03:37AM
Feb-15-24 10:00AM
Jan-03-24 04:01PM
09:55AM
Jan-02-24 08:01AM
Dec-30-23 05:02PM
Nov-21-23 04:01PM
Nov-09-23 02:19PM
Nov-08-23 05:21AM
(FierceBiotech.com) -7.01%
Nov-07-23 04:39PM
(Associated Press Finance)
04:01PM
04:01PM
Nov-03-23 12:01PM
Oct-31-23 04:01PM
12:00PM
Oct-26-23 08:01AM
Oct-17-23 04:21AM
Sep-27-23 09:01AM
Sep-19-23 04:01PM
Aug-08-23 06:01AM
Aug-07-23 04:02PM
Aug-03-23 05:15PM
04:13PM
(Associated Press Finance)
04:01PM
Jul-27-23 08:01AM
Jul-03-23 08:38PM
Jun-21-23 08:00PM
Jun-18-23 10:00AM
May-30-23 06:01PM
May-09-23 01:49PM
(Thomson Reuters StreetEvents)
May-08-23 05:15PM
04:08PM
04:01PM
May-01-23 04:01PM
Apr-26-23 08:00PM
08:01AM
Apr-17-23 01:31PM
Apr-09-23 01:19PM
Mar-14-23 04:31PM
02:56AM
Feb-28-23 05:10AM
Feb-25-23 07:17AM
Feb-23-23 05:25PM
04:01PM
Feb-20-23 10:00AM
Feb-16-23 04:01PM
Feb-07-23 04:01PM
Jan-26-23 02:33PM
Jan-09-23 08:01AM
Jan-05-23 06:30AM
Jan-04-23 04:01PM
Dec-12-22 03:44PM
10:00AM
Nov-30-22 09:55AM
Nov-25-22 12:00PM
Nov-10-22 04:01PM
09:55AM
09:01AM
Nov-07-22 05:25PM
04:01PM
04:01PM
Nov-03-22 09:01AM
Oct-31-22 04:01PM
Oct-28-22 11:58AM
Oct-14-22 09:41AM
Oct-06-22 08:37PM
Oct-05-22 08:01AM
Sep-09-22 08:01AM
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROSA-BJORKESON DAGMAR Director Sep 27 '24 Sale 20.68 2,503 51,762 8,490 Oct 01 04:13 PM RANIERI RICHARD J Director Sep 27 '24 Sale 20.68 2,503 51,762 8,490 Oct 01 04:12 PM GUSTAFSON KURT A Director Sep 27 '24 Sale 20.68 2,503 51,762 9,490 Oct 01 04:10 PM GORMAN KEVIN CHARLES Director Sep 27 '24 Sale 20.68 2,654 54,885 8,392 Oct 01 04:09 PM Montgomery Alan Bruce Director Sep 27 '24 Sale 20.68 1,853 38,320 9,140 Oct 01 04:08 PM Feigal Ellen Director Sep 27 '24 Sale 20.68 2,503 51,762 8,490 Oct 01 04:07 PM GORMAN KEVIN CHARLES Director Sep 27 '24 Proposed Sale 20.68 2,654 54,885 Sep 27 10:58 AM Montgomery Alan Bruce Director Sep 27 '24 Proposed Sale 20.68 1,853 38,320 Sep 27 10:39 AM Feigal Ellen Director Sep 27 '24 Proposed Sale 20.68 2,503 51,762 Sep 27 10:35 AM RANIERI RICHARD J Director Sep 27 '24 Proposed Sale 20.68 2,503 51,762 Sep 27 10:29 AM GUSTAFSON KURT A Director Sep 27 '24 Proposed Sale 20.68 2,503 51,762 Sep 27 10:12 AM ROSA-BJORKESON DAGMAR Director Sep 27 '24 Proposed Sale 20.68 2,503 51,762 Sep 27 09:41 AM Desjarlais John R SR. VICE PRESIDENT & CSO Jul 09 '24 Option Exercise 10.73 42,215 452,967 228,648 Jul 11 06:41 PM Desjarlais John R SR. VICE PRESIDENT & CSO Jul 10 '24 Option Exercise 10.73 7,785 83,533 200,104 Jul 11 06:41 PM Desjarlais John R SR. VICE PRESIDENT & CSO Jul 09 '24 Sale 18.32 36,329 665,511 192,319 Jul 11 06:41 PM Valente Nancy EVP, Chief Development Officer May 02 '24 Sale 23.58 4,745 111,872 55,115 May 03 04:06 PM Kuch John J SR. VICE PRESIDENT & CFO Mar 11 '24 Sale 23.50 849 19,953 121,070 Mar 12 04:08 PM Eckert Celia SVP, GENERAL COUNSEL Mar 11 '24 Sale 23.50 850 19,977 45,465 Mar 12 04:06 PM Desjarlais John R SR. VICE PRESIDENT & CSO Mar 11 '24 Sale 23.50 1,280 30,082 186,433 Mar 12 04:05 PM Dahiyat Bassil I PRESIDENT & CEO Mar 11 '24 Sale 23.50 2,741 64,418 351,894 Mar 12 04:03 PM GUSTAFSON KURT A Director Mar 06 '24 Option Exercise 10.73 15,000 160,950 20,007 Mar 07 04:10 PM GUSTAFSON KURT A Director Mar 06 '24 Sale 23.18 14,000 324,453 6,007 Mar 07 04:10 PM Kuch John J SR. VICE PRESIDENT & CFO Mar 05 '24 Sale 23.43 4,474 104,821 121,919 Mar 07 04:07 PM Desjarlais John R SR. VICE PRESIDENT & CSO Mar 05 '24 Sale 23.43 6,629 155,311 166,989 Mar 07 04:05 PM Eckert Celia SVP, GENERAL COUNSEL Mar 05 '24 Sale 23.43 3,892 91,186 33,226 Mar 07 04:03 PM Dahiyat Bassil I PRESIDENT & CEO Mar 05 '24 Sale 23.43 12,528 293,519 300,097 Mar 07 04:01 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 14 '24 Option Exercise 11.05 11,943 131,970 173,618 Feb 16 04:06 PM GORMAN KEVIN CHARLES Director Feb 13 '24 Buy 19.12 53 1,013 5,060 Feb 15 04:02 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 13 '24 Option Exercise 11.05 68,057 752,030 215,783 Feb 14 02:23 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 13 '24 Sale 19.38 54,108 1,048,743 161,675 Feb 14 02:23 PM Dahiyat Bassil I PRESIDENT & CEO Dec 29 '23 Option Exercise 11.05 65,001 718,261 357,929 Dec 29 04:24 PM Dahiyat Bassil I PRESIDENT & CEO Dec 29 '23 Sale 20.93 45,000 941,670 312,929 Dec 29 04:24 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite